PHASE-II STUDY OF MITOMYCIN-C, ETOPOSIDE AND VINDESINE IN METASTATIC STAGE-IV NON-SMALL-CELL LUNG-CANCER

被引：6

作者：

GRIDELLI, C

PEPE, R

PALMERI, S

IACOBELLI, S

GENTILE, M

GEBBIA, V

GARUFI, C

AIROMA, G

PALMIERI, G

RUSSO, A

INCORONATO, P

DEPLACIDO, S

PERRONE, F

BASILICO, L

RAUSA, L

FERRANTE, G

BIANCO, AR

机构：

[1] NAPLES UNIV,FAC MED 2,CATTEDRA CHIRURG TORAC,I-80138 NAPLES,ITALY

[2] UNIV PALERMO,FAC MED,IST FARMACOL,SEZ ONCOL CLIN,I-90134 PALERMO,ITALY

[3] OSPED SS ANNUNZIATA,DIV RADIOTERAPIA,CHIETI,ITALY

[4] UNIV CHIETI,FAC MED,CATTEDRA ONCOL CLIN,CHIETI,ITALY

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1991年 / 28卷 / 05期

关键词：

MITOMYCIN-C; ETOPOSIDE; VINDESINE; NON-SMALL-CELL LUNG CANCER;

D O I：

10.1007/BF00685698

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A total of 72 patients with metastatic stage IV non-small-cell lung cancer (NSCLC) were treated with combination chemotherapy comprising the MEV regimen (mitomycin C, 8 mg/m2 given i.v. on day 1; etoposide, 100 mg/m2 given i.v. on days 1-3; and vindesine, 3 mg/m2 given i.v. on day 1, treatment repeated every 3 weeks). In 65 evaluable patients, the objective response rate was 37% (complete responses, 4.7%; partial responses, 32.3%). The median survival was 7.6 months for all patients. The treatment was very well tolerated. MEV proved to be an active and non-toxic regimen for the treatment of metastatic NSCLC.

引用

页码：405 / 407

页数：3

共 22 条

[1] COMBINATION CHEMOTHERAPY VERSUS SINGLE AGENTS FOLLOWED BY COMBINATION CHEMOTHERAPY IN STAGE-IV NON-SMALL-CELL LUNG-CANCER - A STUDY OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP [J].

BONOMI, PD ;

FINKELSTEIN, DM ;

RUCKDESCHEL, JC ;

BLUM, RH ;

GREEN, MD ;

MASON, B ;

HAHN, R ;

TORMEY, DC ;

HARRIS, J ;

COMIS, R ;

GLICK, J .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1602-1613

[2]

BONOMI PD, 1986, CANCER TREAT REP, V70, P1447

[3] CIS-PLATINUM AND VINDESINE IN COMBINATION IN THE TREATMENT OF NON-SMALL CELL LUNG-CANCER [J].

CARMICHAEL, J ;

GREGOR, A ;

CORNBLEET, MA ;

ALLAN, SG ;

MCINTYRE, MA ;

GRANT, IWB ;

COMPTON, GK ;

LEONARD, RCF ;

SMYTH, JF .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (07) :811-814

[4]

EAGAN RT, 1978, CANCER TREAT REP, V62, P843

[5]

GATZMEIR U, 1988, LUNG CANCER S, V4, pA125

[6]

GRALLA R J, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P182

[7]

GRALLA RJ, 1989, P AN M AM SOC CLIN, V8, P227

[8] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[9]

KLASTERSKY J, 1986, SEMIN ONCOL, V13, P104

[10]

KRIS MG, 1985, CANCER TREAT REP, V69, P387

← 1 2 3 →